Non-invasive Diagnostics of Liver Fibrosis

1. Blachier M, Leleu H, Peck-Radosavljevic M. The burden of liver disease in Europe: A review of available epidemiological data. J Hepatology, 58, 2013, № 3, 593-608.10.1016/j.jhep.2012.12.00523419824Search in Google Scholar

2. Elpek G. Cellular and molecular mechanisms in the pathogenesis of liver fibrosis: An update. World J Gastroenterol, 20, 2014, № 23, 7260-7276.10.3748/wjg.v20.i23.7260406407224966597Search in Google Scholar

3. Göbel T, Erhardt A, Herwig M, et al. High prevalence of significant liver fibrosis and cirrhosis in chronic hepatitis B patients with normal ALT in central Europe. J Med Virol, 83, 2011, № 6, 968-973.10.1002/jmv.2204821503908Search in Google Scholar

4. Hernandez-Gea V, Scott L. Friedman SL. Pathogenesis of Liver Fibrosis: mechanisms of disease. Ann Rev Pathol, 6, 2011, № 2, 425-456.10.1146/annurev-pathol-011110-13024621073339Search in Google Scholar

5. Iredale JP, Thompson A, Henderson NC. Extracellular matrix degradation in liver fibrosis. Biochim Biophys Acta (BBA), 1832, 2013, № 7, 876-883.10.1016/j.bbadis.2012.11.00223149387Search in Google Scholar

6. Gordon SC, Lamerato LE, Rupp LB et al. Prevalence of Cirrhosis in Hepatitis C Patients in the Chronic Hepatitis Cohort Study (CHeCS): A Retrospective and Prospective Observational Study. Am J Gastroent, 110, 2015, № 8, 1169-1177.10.1038/ajg.2015.203573124226215529Search in Google Scholar

7. Rossi E, Adams LA, Bulsara M et al. Assessing Liver Fibrosis with Serum Marker Models. Clin Biochem Rev, 28, 2007, № 1, 3-10.Search in Google Scholar

8. Baranova A, P. La P, A. Birerdinc. Non-invasive markers for hepatic fibrosis. BMC Gastroenterology, 11, 2011, № 1, 91-98.10.1186/1471-230X-11-91317618921849046Search in Google Scholar

9. Fallatah HI. Noninvasive Biomarkers of Liver Fibrosis: An Overview. Adv Hepat, 2014, 2014, Article ID 357287, 15.10.1155/2014/357287Search in Google Scholar

10. Lombardi R, Buzzetti E, Roccarina D, and Emmanuel A. Non-invasive assessment of liver fibrosis in patients with alcoholic liver disease. World J Gastroenterol, 21, 2015, № 39, 11044-11052.10.3748/wjg.v21.i39.11044460790426494961Search in Google Scholar

11. Gordon SC, Lamerato LE, Rupp LB et al. Prevalence of Cirrhosis in Hepatitis C Patients in the Chronic Hepatitis Cohort Study (CHeCS): A Retrospective and Prospective Observational Study. Am J Gastroent, 110, 2015, № 8, 1169-1177.10.1038/ajg.2015.203Search in Google Scholar

12. Gressner, CF Gao, Gressner OA. Non-invasive biomarkers for monitoring the fibrogenicprocess in liver: A short survey. World J Gastroenterol, 15, 2009, № 20, 2433-2440.10.3748/wjg.15.2433268689819468990Search in Google Scholar

13. Mayeux R. Biomarkers: Potential Uses and Limitations. NeuroRx, 1, 2004, № 2, 182-188. doi:10.1602/neurorx.1.2.182.10.1602/neurorx.1.2.18253492315717018Search in Google Scholar

14. Huang H, Wu T Mao J, et al. CHI3L1 Is a Liver-Enriched, Noninvasive Biomarker That Can Be Used to Stage and Diagnose Substantial Hepatic Fibrosis. J Integrat Biol, 19, 2015, № 6, 339-345.10.1089/omi.2015.0037448671326415140Search in Google Scholar

15. Papastergiou V, Tsochatzis E, Andrew K. Non-invasive assessment of liver fibrosis Ann Gastroenterol, 25, 2012, № 3, 218-231.Search in Google Scholar

16. Cox-North PP, Shuhart MC Core Concepts. Evaluation and Staging of Liver Fibrosis. Last Updated: October 22nd, 2015.Search in Google Scholar

17. Lurie Y, Webb M, Cytter-Kuint R, et al. Non-invasive diagnosis of liver fibrosis and cirrhosis. World J Gastroenterol, 21, 2015, № 41, 11567-11583.10.3748/wjg.v21.i41.11567463196126556987Search in Google Scholar

18. Liu T, Wang X, Karsdal MA, et al. Molecular Serum Markers of Liver Fibrosis. Biomark Insights, 7, 2012, № 1, 105-117.10.4137/BMI.S10009341261922872786Search in Google Scholar

19. Tsochatzis EA, Crossan C Longworth L. Cost-effectiveness of noninvasive liver fibrosis tests for treatment decisions in patients with chronic hepatitis C. Hepatology, 60, 2014, № 3, 832-843.10.1002/hep.27296426529525043847Search in Google Scholar

20. Zhang D, Wang NY, Yang CB, et al. The clinical value of serum connective tissue growth factor in the assessment of liver fibrosis. Dig Dis Sci, 55, 2010, № 3, 767-74.10.1007/s10620-009-0781-919294506Search in Google Scholar

21. Leroy V, Monier M, Bottari S, et al. Circulating Matrix Metalloproteinases 1, 2, 9 and Their Inhibitors TIMP-1 and TIMP-2 as Serum Markers of Liver Fibrosis in Patients With Chronic Hepatitis C: Comparison With PIIINP and Hyaluronic Acid Metalloproteinases and Their Inhibitors as Serum Markers. Am J Gastroent, 99, 2004, № 2, 271-279.10.1111/j.1572-0241.2004.04055.x15046217Search in Google Scholar

22. De Lucca Schiavon L, Narciso-Schiavon J, de Carvalho-Filho R et al. Non-invasive diagnosis of liver fibrosis in chronic hepatitis C. World J Gastroenterol. 20, 2014, № 11, 2854-2866.10.3748/wjg.v20.i11.2854396199224659877Search in Google Scholar

23. Haukeland JW, Lorgen I, Schreiner LT, et al. AST/ALT ratio provides prognostic information independently of Child-Pugh class, gender and age in non-alcoholic cirrhosis. Scand J Gastroenterol, 43, 2008, № 10, 1241-1248.10.1080/0036552080215861418609128Search in Google Scholar

24. Lin ZH, Xin YN, Dong QJ et al. Performance of the aspar-tate aminotransferase-to-platelet ratio index for the staging of hepatitis C-related fibrosis: an updated meta-analysis. Hepatology, 53, 2011, № 3, 726-736.10.1002/hep.24105Search in Google Scholar

25. Wenwen J, Zhonghua L, Yongning X, et al. Diagnostic accuracy of the aspartate aminotransferase-to-platelet ratio index for the prediction of hepatitis B-related fibrosis. Gastroenterol, 12, 2012, № 1, 14. Published online 2012 Feb 14. doi: 10.1186/1471-230X-12-1410.1186/1471-230X-12-14Search in Google Scholar

26. Zaman A, Rosen HR, Ingram K et al. Assessment of FIBRO Spect II to detect hepatic fibrosis in chronic hepatitis C patients. Am J Med, 120, 2007, № 3, 280-291.10.1016/j.amjmed.2006.06.044Search in Google Scholar

27. Salkic NN, Jovanovic P, Hauser G, et al. FibroTest/Fibrosure for significant liver fibrosis and cirrhosis in chronic hepatitis B: a meta-analysis. Am J Gastroenterol, 109, 2014, № 6, 796-806.10.1038/ajg.2014.21Search in Google Scholar

28. Lichtinghagen R, Pietsch D, Bantel H, et al. The Enhanced Liver Fibrosis (ELF) score: Normal values, influence factors and proposed cut-off values. J Hepatology, 59, 2013, № 2, 236-242.10.1016/j.jhep.2013.03.016Search in Google Scholar

29. Parkes J, Guha IN, Roderick P, et al. Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: Validating the European Liver Fibrosis Panel and exploring simple markers. Hepatology, 47, 2008, № 2, 455-460.10.1002/hep.21984Search in Google Scholar

30. Guechot J, Trocme C, Renversez JC et al. Independent validation of the Enhanced Liver Fibrosis (ELF) score in the ANRS HC EP 23 Fibrostar cohort of patients with chronic hepatitis C. Clin Chem Lab Med. 50, 2012, № 4, 693-699.10.1515/cclm-2011-0858Search in Google Scholar

31. Trembling PM, Lampertico P, Parkes J. Performance of Enhanced Liver Fibrosis test and comparison with transient elastography in the identification of liver fibrosis in patients with chronic hepatitis B infection. J Viral Hepat, 21, 2014, № 6, 430-438.10.1111/jvh.12161Search in Google Scholar

32. Boeker KH, Haberkorn CI, Michels D. Diagnostic potential of circulating TIMP-1 and MMP-2 as markers of liver fibrosis in patients with chronic hepatitis C. Clin Chim Acta, 316, 2002, № 1-2, 71-81.10.1016/S0009-8981(01)00730-6Search in Google Scholar